Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and CTLA-4, restore and enhance the body’s immune surveillance and attack ability against tumors by relieving the inhibition of tumor cells on the immune system (24, 25). Here, CTLA4 is linked to neoplasm.